Skip to main content
. Author manuscript; available in PMC: 2015 Sep 19.
Published in final edited form as: Nature. 2014 Dec 22;519(7543):370–373. doi: 10.1038/nature14028

Extended Data Figure 6. siRNA ( siRNATyrRS or siRNAPARP-1), with and without low RSV (5 μM), does not affect cell viability.

Extended Data Figure 6

HeLa cells (1× 106) were reverse-transfected with siRNA targeted to TyrRS or PARP-1. An siRNACon (a scrambled sequence of siRNAPARP-1) was used as a control. Viability was monitored using the RTCA iCELLigence System (ACEA Biosciences). Samples were treated with RSV (5μM) at 60h and monitoring was continued for another 2h for siRNATyrRS (total of 62h of monitoring) and for another 16h for siRNACon and siRNAPARP-1 (total 76h monitoring).